Long lasting fusion peptide inhibitors of viral infection
US7090851B1 · kind B1 · utility
12Cited by
7References
29Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 7, 2000 |
| Grant date | Aug 15, 2006 |
| Priority date | — |
| Expiry date | Jan 4, 2023 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2740/16122
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.